11.10.2023

NeoPhore presented a first disclosure of NP1867 at AACR-NCI-EORTC Conference in Boston, USA

On Saturday October 14th, at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference in Boston, USA NeoPhore presented a first disclosure of NP1867; a potent, selective, covalent small molecule inhibitor of DNA Mismatch Repair (MMR) protein PMS2. We showed, for the first time, that NP1867 functionally inhibits MMR in cells and elicits COSMIC mutational signatures consistent with MMR-deficient patient samples.

To download the poster please submit the form below.

Neophore EORTC Poster

More news

18.04.2023

NeoPhore signs research collaboration with The Institute of Cancer Research, London

London, UK, 18 April 2023, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has signed a strategic c…

19.01.2023

NeoPhore completes extension to Series B financing to further advance discovery pipeline

Scientific milestones achieved significantly ahead of schedule Cambridge, UK, 19 January 2023 – NeoPhore Limited, a small molecule neoantigen i…

28.07.2022

NeoPhore Enters Three Year Research Collaboration with World Leading Oncologist’s Lab at Major US Cancer Center

Cambridge, UK, 28 July 2022, – NeoPhore Limited, a small molecule neoantigen immuno-oncology company, today announces that it has entered a t…

Contact us at info@neophore.com  |  
Call us +44 (0) 330 128 9990